Insulin helps maintain proper blood sugar regulation and supports overall health. Easy to use.
Insulin Isophane
Hypoglycemic agent
Injection solution: 10 mL vial
1 mL contains insulin isophane – 40 IU
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Resistance or partial resistance to oral hypoglycemic agents (used in combination therapy in such cases)
Intercurrent illnesses
Surgical intervention (monotherapy or combination therapy)
Diabetes mellitus during pregnancy (if diet therapy is ineffective)
Administer 30–45 minutes before breakfast, 1–2 times daily (rotate injection sites each time)
In special cases, the doctor may prescribe intramuscular injection
Medium-acting insulin must not be administered intravenously
Dosage is individualized and depends on blood and urine glucose levels, especially during disease progression
Typical dosage: 8–24 IU once daily
In patients highly sensitive to insulin (children or adults), 8 IU/day may be sufficient; in patients with low sensitivity, doses may exceed 24 IU/day
If the morning dose exceeds 0.6 IU/kg, it should be split into two injections at different sites
Patients requiring 100 IU/day or more should be hospitalized when switching insulin
Blood glucose monitoring is necessary when switching from one preparation to another
Hypersensitivity to insulin
Hypoglycemia
Allergic reactions: urticaria, angioneurotic edema (swelling, redness), itching, hypotension
Hypoglycemia: pale skin, increased sweating, tachycardia, tremor, hunger, anxiety, agitation, oral paresthesia, headache, drowsiness, insomnia, fear, depressive mood, irritability, unusual behavior, impaired movement coordination, speech and hearing disorders; hypoglycemic coma
Hyperglycemia and diabetic ketoacidosis: may occur with low doses, missed injections, diet noncompliance, fever, or infection; symptoms include drowsiness, thirst, decreased appetite, facial redness, impaired consciousness (pre-comatose or comatose states), transient visual disturbances (especially at therapy initiation)
Immune reactions: cross-immunologic reactions with human insulin, increased anti-insulin antibody titers leading to increased glycemia
Injection site reactions: erythema, itching, lipodystrophy (atrophy or hypertrophy of subcutaneous fat); swelling and refractive disturbances may occur at the start of therapy but are usually temporary and resolve with continued treatment
